c4 therapeutics inc. - CCCC
CCCC
Close Chg Chg %
4.01 0.24 5.99%
Closed Market
4.25
+0.24 (5.99%)
Volume: 1.36M
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: c4 therapeutics inc. - CCCC
CCCC Key Data
| Open $4.00 | Day Range 3.92 - 4.34 |
| 52 Week Range 1.06 - 11.88 | Market Cap $283.06M |
| Shares Outstanding 70.59M | Public Float 56.67M |
| Beta 3.06 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.70 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.02M |
CCCC Performance
| 1 Week | -1.39% | ||
| 1 Month | -27.84% | ||
| 3 Months | -35.99% | ||
| 1 Year | 177.78% | ||
| 5 Years | N/A |
CCCC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About c4 therapeutics inc. - CCCC
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
CCCC At a Glance
C4 Therapeutics, Inc.
490 Arsenal Way
Watertown, Massachusetts 02472
| Phone | 1-617-231-0700 | Revenue | 20.76M | |
| Industry | Biotechnology | Net Income | -132,493,000.00 | |
| Sector | Health Technology | Employees | 145 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
CCCC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.513 |
| Price to Book Ratio | 1.388 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.745 |
| Enterprise Value to Sales | 4.71 |
| Total Debt to Enterprise Value | 0.726 |
CCCC Efficiency
| Revenue/Employee | 143,144.828 |
| Income Per Employee | -913,744.828 |
| Receivables Turnover | 1.759 |
| Total Asset Turnover | 0.051 |
CCCC Liquidity
| Current Ratio | 6.341 |
| Quick Ratio | 6.341 |
| Cash Ratio | 5.932 |
CCCC Profitability
| Gross Margin | 62.724 |
| Operating Margin | -669.835 |
| Pretax Margin | -632.169 |
| Net Margin | -638.336 |
| Return on Assets | -32.824 |
| Return on Equity | -49.498 |
| Return on Total Capital | -41.784 |
| Return on Invested Capital | -38.896 |
CCCC Capital Structure
| Total Debt to Total Equity | 28.839 |
| Total Debt to Total Capital | 22.384 |
| Total Debt to Total Assets | 18.854 |
| Long-Term Debt to Equity | 26.718 |
| Long-Term Debt to Total Capital | 20.738 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for C4 Therapeutics Inc. - CCCC
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 33.20M | 45.78M | 31.10M | 20.76M | |
Sales Growth
| +55.25% | +37.93% | -32.08% | -33.25% | |
Cost of Goods Sold (COGS) incl D&A
| - | 2.91M | 7.57M | 7.74M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.84M | 2.91M | 7.57M | 7.74M | |
Depreciation
| 2.84M | 2.91M | 7.57M | 7.74M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | +160.47% | +2.18% | - |
Gross Income
| - | 42.88M | 23.52M | 13.02M | |
Gross Income Growth
| - | - | -45.14% | -44.66% | - |
Gross Profit Margin
| - | +93.65% | +75.65% | +62.72% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 90.80M | 125.01M | 153.06M | 152.05M | |
Research & Development
| 76.82M | 94.67M | 117.84M | 117.71M | |
Other SG&A
| 13.98M | 30.35M | 35.22M | 34.34M | |
SGA Growth
| +67.86% | +37.67% | +22.43% | -0.66% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 5.68M | 621.00K | - |
EBIT after Unusual Expense
| (66.13M) | (82.13M) | (129.53M) | (139.65M) | |
Non Operating Income/Expense
| 393.00K | 387.00K | 3.58M | 9.81M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.23M | 2.15M | 2.22M | 1.37M | |
Interest Expense Growth
| - | +74.53% | +3.31% | -38.04% | |
Gross Interest Expense
| 1.23M | 2.15M | 2.22M | 1.37M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (66.96M) | (83.89M) | (128.18M) | (131.21M) | |
Pretax Income Growth
| -101.11% | -25.28% | -52.79% | -2.37% | |
Pretax Margin
| -201.72% | -183.23% | -412.19% | -632.17% | |
Income Tax
| - | - | (626.00K) | 1.28M | - |
Income Tax - Current - Domestic
| - | - | (626.00K) | 76.00K | - |
Income Tax - Current - Foreign
| - | - | - | 1.20M | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (66.33M) | (83.89M) | (128.18M) | (132.49M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (66.33M) | (83.89M) | (128.18M) | (132.49M) | |
Net Income Growth
| -94.54% | -26.47% | -52.79% | -3.37% | |
Net Margin Growth
| -199.83% | -183.23% | -412.19% | -638.34% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (66.33M) | (83.89M) | (128.18M) | (132.49M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (66.33M) | (83.89M) | (128.18M) | (132.49M) | |
EPS (Basic)
| -1.5405 | -1.8221 | -2.6232 | -2.669 | |
EPS (Basic) Growth
| -55.56% | -18.28% | -43.97% | -1.75% | |
Basic Shares Outstanding
| 43.06M | 46.04M | 48.86M | 49.64M | |
EPS (Diluted)
| -1.5405 | -1.8221 | -2.6232 | -2.669 | |
EPS (Diluted) Growth
| -55.56% | -18.28% | -43.97% | -1.75% | |
Diluted Shares Outstanding
| 43.06M | 46.04M | 48.86M | 49.64M | |
EBITDA
| (57.61M) | (79.23M) | (121.96M) | (131.29M) | |
EBITDA Growth
| -76.10% | -37.53% | -53.94% | -7.65% | |
EBITDA Margin
| -173.54% | -173.04% | -392.21% | -632.56% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 15.00 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.487 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -1.508 | |
| Last Quarter’s Earnings | -0.35 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.67 | Next Fiscal Year Estimate | -1.567 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 3 | 8 | 9 |
| Mean Estimate | -0.49 | 0.19 | -1.51 | -1.57 |
| High Estimates | -0.41 | 1.52 | -1.44 | 0.36 |
| Low Estimate | -0.59 | -0.49 | -1.61 | -2.36 |
| Coefficient of Variance | -11.79 | 604.23 | -3.80 | -49.02 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 4 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for C4 Therapeutics Inc. - CCCC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for C4 Therapeutics Inc. - CCCC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 12, 2024 | Leonard M. J. Reyno Chief Medical Officer | 91,809 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5 per share | 459,045.00 |
| Jul 3, 2024 | Kenneth C. Anderson Director | 114,671 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $4.85 per share | 556,154.35 |
| Jul 3, 2024 | Donna Roy Grogan Director | 26,468 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $4.85 per share | 128,369.80 |
| Jun 12, 2024 | Ronald H. W. Cooper Director | 65,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 11, 2024 | Mark Mossler Chief Accounting Officer | 27,430 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 11, 2024 | Mark Mossler Chief Accounting Officer | 19,790 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Stewart Fisher Chief Scientific Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 11, 2024 | Stewart Fisher Chief Scientific Officer | 94,950 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Stewart Fisher Chief Scientific Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 11, 2024 | Jolie M. Siegel Chief Legal Officer | 90,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Jolie M. Siegel Chief Legal Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 11, 2024 | Jolie M. Siegel Chief Legal Officer | 84,850 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Jolie M. Siegel Chief Legal Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 11, 2024 | Stewart Fisher Chief Scientific Officer | 118,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Kendra R. Adams Chief Financial Officer | 45,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Kendra R. Adams Chief Financial Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 11, 2024 | Scott N. Boyle Chief Business Officer | 115,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Kelly Schick Chief People Officer | 78,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Kelly Schick Chief People Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Mar 11, 2024 | Kelly Schick Chief People Officer | 92,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |